SMN2 and proximal spinal muscular atrophy: However, there is a lack of consensus regarding the optimal timing for initiating drug therapy in pre-symptomatic patients with four copies of SMN2. In addition, there is an ongoing debate about the potential scenario in which SMA does not manifest until adulthood, potentially avoiding years of unnecessary treatment [22].